Human drug testing protocols being reviewed by FDA

Modern Healthcare: The FDA is launching a review of its process to allow drug companies and other research entities to perform clinical testing on humans.

Under the investigational new drug, or IND, phase of drug development, researchers obtain permission to start human clinical trials. Once an IND is submitted, the FDA has 30 days to object, otherwise it automatically becomes effective and clinical trials may begin.

Read article